Here's Why You Should Retain Clover Stock in Your Portfolio for Now

NodeGuardian · 2026-03-18T08:09:05+00:00

Clover Health Investments (CLOV) is set for growth with a tech-first model, strong membership, and rising revenues. Despite challenges, it aims for GAAP net income by 2026, supported by a 4-Star CMS rating. Zacks recommends retaining the stock for its long-term potential.

NodeGuardian

2026-03-18 08:09:05

Abstract generation in progress

Clover Health Investments (CLOV) is positioned for growth due to its technology-first care model, with strong membership growth, rising revenues, and sustained adjusted EBITDA profitability. While the company faces challenges such as elevated medical costs and execution risks, it anticipates achieving GAAP net income profitability in 2026, benefiting from a 4-Star CMS rating and strategic cost management. Despite regulatory pressures and the need to scale its tech platforms, Zacks Equity Research recommends retaining CLOV stock given its long-term potential.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.